OVID Ovid Therapeutics Inc

Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that it will host a Research & Development (R&D) Day investor event on Monday, October 2, 2023. The event will take place at the Company’s headquarters in New York’s Hudson Yards from 12:00 pm - 2:30 pm and will be webcast simultaneously.

Ovid management will provide updates on Ovid’s scientific strategy and anticipated clinical development plans. Additionally, the Company’s research and development leadership will review new data characterizing how the unique mechanisms of action in its pipeline address the underlying causes of neuronal hyperexcitability and may hold broader therapeutic potential in other central nervous system disorders. Also presenting will be recognized clinicians and academic thought leaders in epilepsy and rare neurological disorders, including:

• Imad Najm, M.D. – Vice Chair for Strategy and Development at the Cleveland Clinic Neurological Institute; Director of the Cleveland Clinic Epilepsy Center
• Connie Lee, Psy.D. – Chief Executive Officer and founding President of the Alliance to Cure Cavernous Malformation

• Stephen Moss, Ph.D. – Director of the Moss Labs for Neuropharmacology within Tufts University Neuroscience Department

In-person attendance is by invitation only. Those who would like to attend should contact Argot Partners on behalf of Ovid. Lunch will be served prior to the event for those attending in-person.

A live webcast of the presentation can be accessed through the Events and Presentations section of the Company’s website at https://investors.ovidrx.com. An archived replay of the webcast will be available on the Company’s website following the live presentation.

About Ovid Therapeutics

Ovid Therapeutics Inc. is a New York-based biopharmaceutical company striving to conquer seizures and intractable brain disorders with courageous science. The Company is advancing a focused pipeline of targeted small molecule candidates to modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitation, which can cause seizures and other neuropathological symptoms. Programs Ovid seeks to develop include: GV101, a potent and highly selective ROCK2 inhibitor, for the potential treatment of lesions associated with cerebral cavernous malformations; OV329, a GABA-aminotransferase inhibitor, for the potential treatment of treatment-resistant seizures; and OV350, a direct activator of the KCC2 transporter, for the potential treatment of epilepsies. In addition, the Company's ROCK2 inhibitor and KCC2 activator portfolios have the potential to treat other neurological conditions. Ovid also maintains a significant financial interest in the future regulatory development and potential commercialization of soticlestat, which Takeda is responsible for advancing globally. Soticlestat is a cholesterol 24-hydroxylase inhibitor, which is currently in Phase 3 trials for Dravet and Lennox-Gastaut syndromes. For more information about these and other Ovid research programs, please visit www.ovidrx.com.

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation: statements regarding the potential use of OV329, GV101 and OV350; the potential development of OV329, GV101 and the library of ROCK2 inhibitors and OV350 and other KCC2 compounds in Ovid’s library; the potential therapeutic opportunity of OV329, GV101 and other ROCK2 inhibitors and OV350 and other KCC2 inhibitors; the potential opportunity for soticlestat; and the timing of Takeda’s two pivotal Phase 3 trials evaluating soticlestat for Dravet syndrome and Lennox-Gastaut syndrome. You can identify forward-looking statements because they contain words such as “anticipates,” “believes,” “expected,” “intends,” “may,” “plan,” “potentially,” “seek,” “strive,” and “will,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Ovid’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, uncertainties inherent in the preclinical and clinical development and regulatory approval processes, risks related to Ovid’s ability to achieve its financial objectives, the risk that Ovid may not be able to realize the intended benefits of its technology or its business strategy, or risks related to Ovid’s ability to identify business development targets or strategic partners, to enter into strategic transactions on favorable terms, or to consummate and realize the benefits of any business development transactions. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth under the caption “Risk Factors” in Ovid’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on August 4, 2023, and in future filings Ovid makes with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Ovid assumes no obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

ContactsInvestors and Media:Maeve ConneightonArgot Partners (on behalf of Ovid)212-596-7231ovid@argotpartners.com